MedTrace Logo

Improving Patient-clinician Communication About End-of-life Care

NCT00374010 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-05-31

No results posted yet for this study

Summary

The specific aims are:

1. to evaluate the feasibility and acceptability of PC-ACP among African American patients with End-stage Renal Disease and their surrogates and
2. to examine preliminary effects of PC-ACP on patient and surrogate outcomes (patients' perceived quality of communication, surrogates' level of comfort in decision making for the patient, patients' difficulty in making choices, patient-surrogate congruence in goals of care, and patients' and surrogates' psychosocial/spiritual receptiveness) at one week following receipt of the intervention.

Conditions

  • End-stage Renal Disease

Interventions

BEHAVIORAL

Patient-Centered Advance Care Planning

The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour: 1. Representational assessment (10 - 15 minutes); 2. Exploring concerns related to planning for future medical decision-making (10 - 15 minutes); 3. Creating conditions for conceptual change (5 minutes); 4. Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and 5. Summary (3 - 5 minutes)

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Mi-Kyung Song, PhD · University of Pittsburgh School of Nursing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-06-30
Completion
2008-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00374010 on ClinicalTrials.gov